New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

Article Details

Citation

Copy to clipboard

Chung SS

New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

Ther Adv Neurol Disord. 2010 Mar;3(2):77-83. doi: 10.1177/1756285609355850.

PubMed ID

21179600 [ View in PubMed

]

Abstract

More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common therapeutic option when surgical treatment cannot be offered. The most recently approved AED in Europe and the USA is lacosamide (LCM), which offers new mechanisms of action and favorable safety profiles. This article reviews LCM's molecular mechanisms of action, pharmacokinetic profiles as well as efficacy and safety from phase II and III clinical trials. In addition, comparison between LCM and other existing AEDs is discussed.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Lacosamide	Cytochrome P450 2C19	Protein	Humans	Unknown	Substrate	Details